Imatinib mesylate (STI-571) is potent tyrosine kinase inhibitors against PDGFR signaling and was originally developed for the treatment of chronic myelogenous leukemia (CML). Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.